Curcumin: A new paradigm and therapeutic opportunity for the treatment of osteoarthritis: Curcumin for osteoarthritis management

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-9

  Henrotin, Yves ^a,b   Priem, Fabian ^c   Mobasheri, Ali ^d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Princess Paola Hospital   (Belgium)

^c Bioxtract S A Parc Scientifique Créalys   (Belgium)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Bioavailability; Clinical trial; Curcumin; Osteoarthritis

Indexed keywords

EID: 84876592147     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-56     Document Type: Review

References (69)

1. Aggarwal BB (2010) Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 30:173-199. doi:10.1146/annurev.nutr.012809.104755
2. Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. TIPS 30(2):85-94. doi:10.1016/j.tips.2008.11.002
3. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006) Inflammation and cancer: how hot is the link? Biochem Pharmacol 72(11):1605-1621. doi:10.1016/j.bcp.2006.06.029
4. Ameye LG, Chee WS (2006) Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther 8(4):R127
5. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharmaceutics 4(6):807-818. doi:10.1021/mp700113r
6. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB (2010) Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 79(3):330-338. doi:10.1016/j.bcp.2009.09.003
7. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC (2011) Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) 4(8):1158-1171. doi:10.1158/1940-6207.CAPR-10-0006
8. Basnet P, Skalko-Basnet N (2011) Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16(6):4567-4598. doi:10.3390/molecules16064567
9. Basnet P, Hussain H, Tho I, Skalko-Basnet N (2012) Liposomal delivery system enhances anti-inflammatory properties of curcumin. J Pharma Sci 101(2):598-609. doi:10.1002/jps.22785
10. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G (2010) Efficacy and safety of Meriva(R), a curcuminphosphatidylcholine complex, during extended administration in osteoarthritis patients. Alternative Med Rev: J Clin Therapeutic 15(4):337-344
11. Buhrmann C, Mobasheri A, Matis U, Shakibaei M (2010) Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther 12(4):R127. doi:10.1186/ar3065
12. Buhrmann C, Mobasheri A, Busch F, Aldinger C, Stahlmann R, Montaseri A, Shakibaei M (2011) Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 286(32):28556-28566. doi:10.1074/jbc.M111.256180
13. Bustanji Y, Taha MO, Almasri IM, Al-Ghussein MA, Mohammad MK, Alkhatib HS (2009) Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation. J Enzyme Inhibition Med Chem 24(3):771-778. doi:10.1080/ 14756360802364377
14. Chan MM (1995) Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 49(11):1551-1556
15. Chandran B, Goel A (2012) A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis. Phytother Res: PTR. doi:10.1002/ptr.4639
16. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21(4B):2895-2900
17. Chowdhury TT, Salter DM, Bader DL, Lee DA (2008) Signal transduction pathways involving p38 MAPK, JNK, NFkappaB and AP-1 influences the response of chondrocytes cultured in agarose constructs to IL-1beta and dynamic compression. Inflammation Res: J Eu Histamine Res Soc [et al] 57(7):306-313. doi:10.1007/s00011-007-7126-y
18. Clutterbuck AL, Mobasheri A, Shakibaei M, Allaway D, Harris P (2009) Interleukin-1beta-induced extracellular matrix degradation and glycosaminoglycan release is inhibited by curcumin in an explant model of cartilage inflammation. Annals of the New York Acad Sci 1171:428-435. doi:10.1111/ j.1749-6632.2009.04687.x
19. Csaki C, Mobasheri A, Shakibaei M (2009) Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 11(6):R165. doi:10.1186/ar2850
20. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res: J Am Assoc Cancer Res 14(14):4491-4499. doi:10.1158/1078-0432.CCR-08-0024
21. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. BJC 90(5):1011-1015. doi:10.1038/sj.bjc.6601623
22. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol, Biomarkers & Prevention: Am Assoc Cancer Res Am Soc Preventive Oncol 14(1):120-125
23. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 75(4):787-809. doi:10.1016/j.bcp. 2007.08.016
24. Gupta SC, Patchva S, Aggarwal BB (2012a) Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. AAPS J. doi:10.1208/s12248-012-9432-8
25. Gupta SC, Patchva S, Koh W, Aggarwal BB (2012b) Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39(3):283-299. doi:10.1111/j.1440-1681.2011.05648.x
26. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV (2008) Curcumin: from ancient medicine to current clinical trials. CMLS 65(11):1631-1652. doi:10.1007/ s00018-008-7452-4
27. Heath DD, Pruitt MA, Brenner DE, Rock CL (2003) Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 783(1):287-295
28. Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, Shakibaei M, Mobasheri A (2010) Biological actions of curcumin on articular chondrocytes. Osteoarthritis and cartilage/OARS, Osteoarthritis Res Soc 18 (2):141-149. doi:10.1016/j.joca.2009.10.002
29. Henrotin Y, Lambert C, Couchourel D, Ripoll C, Chiotelli E (2011) Nutraceuticals: do they represent a new era in the management of osteoarthritis?-a narrative review from the lessons taken with five products. Osteoarthritis and cartilage/OARS, Osteoarthritis Res Soc 19(1):1-21. doi:10.1016/j. joca.2010.10.017
30. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A (2001) Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61(3):1058-1064
31. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, Gescher AJ (2002) Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol, Biomarkers Prevention:Am Assoc Cancer Res, Am Soc Preventive Oncol 11(1):105-111
32. Irving GR, Howells LM, Sale S, Kralj-Hans I, Atkin WS, Clark SK, Britton RG, Jones DJ, Scott EN, Berry DP, Hemingway D, Miller AS, Brown K, Gescher AJ, Steward WP (2012) Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration-a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila). doi:10.1158/1940-6207.CAPR-12-0281
33. Jaiswal AS, Marlow BP, Gupta N, Narayan S (2002) Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21(55):8414-8427. doi:10.1038/sj.onc.1205947
34. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62(12):1145-1155
35. Kalra EK (2003) Nutraceutical-definition and introduction. AAPS PharmSci 5(3):E25. doi:10.1208/ps050325
36. Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B (1991) Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebocontrolled, cross-over study. J Ethnopharmacol 33(1-2):91-95
37. Kurien BT, Scofield RH (2007) Curcumin/turmeric solubilized in sodium hydroxide inhibits HNE protein modification-an in vitro study. J Ethnopharmacol 110(2):368-373. doi:10.1016/j.jep. 2006.09.034
38. Kurien BT, Singh A, Matsumoto H, Scofield RH (2007) Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev 5(4):567-576. doi:10.1089/adt.2007.064
39. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC CAM 6:10. doi:10.1186/1472-6882-6-10
40. Masuda T, Hidaka K, Shinohara A, Maekawa T, Takeda Y, Yamaguchi H (1999) Chemical studies on antioxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin. J Agric Food Chem 47(1):71-77
41. Mathy M, Sanchez C, Priem F, Henrotin Y (2007) Curcumin inhibits interleukin-6,-8, nitric oxide and prostaglandin E2 synthesis by bovine chondrocytes. Osteoarthr Cartil/OARS, Osteoarthr Res Soc 15(Suppl C):C115
42. Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y (2009) Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res: J EHRS [et al] 58(12):899-908. doi:10.1007/s00011-009-0063-1
43. Padhye S, Chavan D, Pandey S, Deshpande J, Swamy KV, Sarkar FH (2010) Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem 10(5):372-387
44. Pan MH, Lin-Shiau SY, Lin JK (2000) Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharm 60(11):1665-1676
45. Pendurthi UR, Rao LV (2000) Suppression of transcription factor Egr-1 by curcumin. Thromb Res 97(4):179-189
46. Ravindranath V, Chandrasekhara N (1981) Metabolism of curcumin-studies with [3H]curcumin. Toxicology 22(4):337-344
47. Ryu MJ, Cho M, Song JY, Yun YS, Choi IW, Kim DE, Park BS, Oh S (2008) Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun 377(4):1304-1308. doi:10.1016/j.bbrc.2008.10.171
48. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB (2007) Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROSindependent mechanism. Carcinogenesis 28(8):1765-1773. doi:10.1093/ carcin/bgm123
49. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A (2007) Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 73(9):1434-1445. doi:10.1016/j.bcp. 2007.01.005
50. Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti C, Manson MM, Marnett LJ, Steward WP, Gescher A (2001) Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res: J Am Assoc Cancer Res 7(5):1452-1458
51. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res: J Am Assoc Cancer Res 10(20):6847-6854. doi:10.1158/1078-0432.CCR-04-0744
52. Sharma RA, Gescher AJ, Steward WP (2005) Curcumin: the story so far. Eur J Cancer 41(13):1955-1968. doi:10.1016/j.ejca.2005.05.009
53. Shen L, Ji H-F (2012) The pharmacology of curcumin: is it the degradation products? Trends Mol Med 18(3):138-144. doi:10.1016/j.molmed.2012.01.004
54. Shen C-L, Smith BJ, Lo D-F, Chyu M-C, Dunn DM, Chen C-H, Kwun I-S (2012) Dietary polyphenols and mechanisms of osteoarthritis. J Nutr Biochem 23(11):1367-1377. doi:http://dx.doi.org/10.1016/j.jnutbio.2012.04.001
55. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64(4):353-356. doi:10.1055/s-2006-957450
56. Singh S, Aggarwal BB (1995) Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270(42):24995-25000
57. Tang Y, Zheng S, Chen A (2009) Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 150(7):3011-3020. doi:10.1210/en.2008-1601
58. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE (2008) Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidem Biomar Prevention: Am Assoc Cancer Res Am Soc Preventive Oncol 17(6):1411-1417. doi:10.1158/1055-9965.EPI-07-2693
59. Velasquez MT, Katz JD (2010) Osteoarthritis: another component of metabolic syndrome? Metab Syndr Relat Disorders 8(4):295-305. doi:10.1089/ met.2009.0110
60. Wahlstrom B, Blennow G (1978) A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol 43(2):86-92
61. Wang SL, Li Y, Wen Y, Chen YF, Na LX, Li ST, Sun CH (2009) Curcumin, a potential inhibitor of up-regulation of TNF-alpha and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway. BES 22(1):32-39. doi:10.1016/S0895-3988(09)60019-2
62. Weisberg SP, Leibel R, Tortoriello DV (2008) Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149(7):3549-3558. doi:10.1210/en.2008-0262
63. Woo HM, Kang JH, Kawada T, Yoo H, Sung MK, Yu R (2007) Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci 80(10):926-931. doi:10.1016/j.lfs.2006.11.030
64. Xia Y, Jin L, Zhang B, Xue H, Li Q, Xu Y (2007) The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci 80(23):2161-2169. doi:10.1016/j.lfs.2007.04.008
65. Xu J, Fu Y, Chen A (2003) Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 285(1): G20-G30. doi:10.1152/ajpgi.00474.2002
66. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, Leeb B, Lequesne M, Lohmander S, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Swoboda B, Varatojo R, Verbruggen G, Zimmermann-Gorska I, Dougados M (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64(5):669-681. doi:10.1136/ard.2004.028886
67. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2007) OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr Cartilage/OARS, Osteoarthr Res Soc 15(9):981-1000. doi:10.1016/j.joca.2007.06.014
68. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidencebased, expert consensus guidelines. Osteoarthr Cartilage/OARS, Osteoarthr Res Soc 16(2):137-162. doi:10.1016/j.joca.2007.12.013
69. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Res Soc 18(4):476-499. doi:10.1016/j. joca.2010.01.013